疑难病杂志2012，Vol.11Issue(5)：334-336,3.DOI:10.3969/j.issn.1671-6450.2012.05.004
盐酸曲美他嗪治疗慢性肺源性心脏病心力衰竭34例临床观察
Clinical effect of trimetazidine dihydrochloride on heart function in 34 patients with chronic pulmonary heart disease
陈娟 1胡晓军 1王四坤 1蒋毅2
作者信息
- 1. 430015,武汉,湖北省新华医院心内科
- 2. 430015,武汉,湖北省新华医院风湿科
- 折叠
摘要
Abstract
Objective To observe the effect of trimetazidine dihydrochloride on heart function in patients with chronic pulmonary heart disease. Methods Sixty four patients with chronic pulmonary heart disease were randomly divided into routine treatment group ( n = 30 ) and trimetazidine dihydrochloride treatment group ( n = 34 ). Patients in treatment group were given both the routine treatment and trimetazidine 20 mg, 3 times daily for 8 weeks; while patients in routine treatment group were given only the routine treatment. These patients were followed up for 8 weeks, clinical and laboratory data were recorded before and after follow-up which included symptoms, signs, left ventricular ejection fraction ( LVEF ), cardiac index ( CI ), cardiac output ( CO ), arterial oxygen pressure ( PaO2 ), arterial carbon dioxide pressure ( PaCO2 ), mean pulmonary artery pressure ( MPAP ). Results Compared with the routine treatment group, trimetazidine treatment group significantly released the clinical symptoms of heart failure in patients with chronic pulmonary heart disease, and the total effective rate in treatment group ) were significantly higher than those in routine treatment group ( ( 91. 18% vs 80. 00% , P <0. 05 ). The LVEF ( P < 0.05 ), CI ( P <0. 05 ), CO ( P < 0. 05 ), and hypoxia ( P < 0. 05 ) in treatment group were significantly improved than those before treatment and control group. Conclusion Trimetazidine dihydrochloride can improve heart function in patients with chronic pulmonary heart disease based on the conventional treatments.关键词
盐酸曲美他嗪/肺源性心脏病/心力衰竭Key words
Trimetazidine dihydrochloride/Pulmonary heart disease/ Heart failure引用本文复制引用
陈娟,胡晓军,王四坤,蒋毅..盐酸曲美他嗪治疗慢性肺源性心脏病心力衰竭34例临床观察[J].疑难病杂志,2012,11(5):334-336,3.
